

Raimondo Bruno

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/801069/publications.pdf>

Version: 2024-02-01

262
papers

7,183
citations

50170

46
h-index

102304

66
g-index

264
all docs

264
docs citations

264
times ranked

6883
citing authors

#	ARTICLE	IF	CITATIONS
1	Refining the estimation of illicit drug consumptions from wastewater analysis: Co-analysis of prescription pharmaceuticals and uncertainty assessment. <i>Water Research</i> , 2011, 45, 4437-4448.	5.3	196
2	New psychoactive substances: challenges for drug surveillance, control, and public health responses. <i>Lancet, The</i> , 2019, 394, 1668-1684.	6.3	195
3	Effect of cannabis use in people with chronic non-cancer pain prescribed opioids: findings from a 4-year prospective cohort study. <i>Lancet Public Health, The</i> , 2018, 3, e341-e350.	4.7	172
4	Prescription of opioid analgesics and related harms in Australia. <i>Medical Journal of Australia</i> , 2011, 195, 280-284.	0.8	157
5	Comparison of unlimited numbers of rapid transcranial magnetic stimulation (rTMS) and ECT treatment sessions in major depressive episode. <i>International Journal of Neuropsychopharmacology</i> , 2000, 3, 129-134.	1.0	124
6	The epidemiology of methamphetamine use and harm in Australia. <i>Drug and Alcohol Review</i> , 2008, 27, 243-252.	1.1	118
7	Is ecstasy a drug of dependence?. <i>Drug and Alcohol Dependence</i> , 2010, 107, 1-10.	1.6	115
8	The Pain and Opioids IN Treatment study. <i>Pain</i> , 2015, 156, 231-242.	2.0	104
9	Using quantitative wastewater analysis to measure daily usage of conventional and emerging illicit drugs at an annual music festival. <i>Drug and Alcohol Review</i> , 2013, 32, 594-602.	1.1	103
10	Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. <i>Pain Medicine</i> , 2015, 16, 356-366.	0.9	102
11	Profiles of illicit drug use during annual key holiday and control periods in Australia: wastewater analysis in an urban, a semi-rural and a vacation area. <i>Addiction</i> , 2013, 108, 556-565.	1.7	101
12	Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. <i>Drug and Alcohol Dependence</i> , 2015, 147, 144-150.	1.6	97
13	The Australian drug harms ranking study. <i>Journal of Psychopharmacology</i> , 2019, 33, 759-768.	2.0	91
14	The Subjective Physiological, Psychological, and Behavioral Risk-Taking Consequences of Alcohol and Energy Drink Co-Ingestion. <i>Alcoholism: Clinical and Experimental Research</i> , 2012, 36, 2008-2015.	1.4	87
15	Estimating daily and diurnal variations of illicit drug use in Hong Kong: A pilot study of using wastewater analysis in an Asian metropolitan city. <i>Forensic Science International</i> , 2013, 233, 126-132.	1.3	86
16	Spatial variations in the consumption of illicit stimulant drugs across Australia: A nationwide application of wastewater-based epidemiology. <i>Science of the Total Environment</i> , 2016, 568, 810-818.	3.9	84
17	Shame and guilt-proneness: Divergent implications for problematic alcohol use and drinking to cope with anxiety and depression symptomatology. <i>Personality and Individual Differences</i> , 2012, 53, 613-617.	1.6	79
18	An analysis of ethical issues in using wastewater analysis to monitor illicit drug use. <i>Addiction</i> , 2012, 107, 1767-1773.	1.7	78

#	ARTICLE	IF	CITATIONS
19	Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015, 16, 1745-1758.	0.9	78
20	Parental Supply of Alcohol in Childhood and Risky Drinking in Adolescence: Systematic Review and Meta-Analysis. <i>International Journal of Environmental Research and Public Health</i> , 2017, 14, 287.	1.2	76
21	The rise of new psychoactive substance use in Australia. <i>Drug Testing and Analysis</i> , 2014, 6, 846-849.	1.6	70
22	The prevalence and correlates of chronic pain and suicidality in a nationally representative sample. <i>Australian and New Zealand Journal of Psychiatry</i> , 2015, 49, 803-811.	1.3	69
23	Trends in morphine prescriptions, illicit morphine use and associated harms among regular injecting drug users in Australia. <i>Drug and Alcohol Review</i> , 2006, 25, 403-412.	1.1	68
24	Nabiximols for the Treatment of Cannabis Dependence. <i>JAMA Internal Medicine</i> , 2019, 179, 1242.	2.6	68
25	Pill testing or drug checking in Australia: Acceptability of service design features. <i>Drug and Alcohol Review</i> , 2018, 37, 226-236.	1.1	67
26	Systematic and Day-to-Day Effects of Chemical-Derived Population Estimates on Wastewater-Based Drug Epidemiology. <i>Environmental Science & Technology</i> , 2015, 49, 999-1008.	4.6	65
27	Age of Alcohol Initiation and Progression to Binge Drinking in Adolescence: A Prospective Cohort Study. <i>Alcoholism: Clinical and Experimental Research</i> , 2018, 42, 100-110.	1.4	65
28	A Roadmap for Integrating Neuroscience Into Addiction Treatment: A Consensus of the Neuroscience Interest Group of the International Society of Addiction Medicine. <i>Frontiers in Psychiatry</i> , 2019, 10, 877.	1.3	64
29	The Impact of Alcohol and Energy Drink Consumption on Intoxication and Risk-Taking Behavior. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 1234-1242.	1.4	63
30	The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 521-538.	0.9	63
31	Who sells what? Country specific differences in substance availability on the Agora cryptomarket. <i>International Journal of Drug Policy</i> , 2016, 35, 16-23.	1.6	63
32	Measuring spatial and temporal trends of nicotine and alcohol consumption in Australia using wastewater-based epidemiology. <i>Addiction</i> , 2018, 113, 1127-1136.	1.7	62
33	Cocaine, MDMA and methamphetamine residues in wastewater: Consumption trends (2009-2015) in South East Queensland, Australia. <i>Science of the Total Environment</i> , 2016, 568, 803-809.	3.9	61
34	Association of parental supply of alcohol with adolescent drinking, alcohol-related harms, and alcohol use disorder symptoms: a prospective cohort study. <i>Lancet Public Health</i> , The, 2018, 3, e64-e71.	4.7	61
35	“High” risk? A systematic review of the acute outcomes of mixing alcohol with energy drinks. <i>Addiction</i> , 2014, 109, 1612-1633.	1.7	60
36	A National Wastewater Monitoring Program for a better understanding of public health: A case study using the Australian Census. <i>Environment International</i> , 2019, 122, 400-411.	4.8	59

#	ARTICLE	IF	CITATIONS
37	Can the Severity of Dependence Scale Be Usefully Applied to "Ecstasy"? <i>Neuropsychobiology</i> , 2009, 60, 137-147.	0.9	58
38	Patterns of use and motivations for consuming alcohol mixed with energy drinks.. <i>Psychology of Addictive Behaviors</i> , 2013, 27, 202-206.	1.4	58
39	Agreement between definitions of pharmaceutical opioid use disorders and dependence in people taking opioids for chronic non-cancer pain (POINT): a cohort study. <i>Lancet Psychiatry</i> ,the, 2015, 2, 314-322.	3.7	55
40	Preliminary Development of a Brief Cannabis Use Disorder Screening Tool: The Cannabis Use Disorder Identification Test Short-Form. <i>Cannabis and Cannabinoid Research</i> , 2016, 1, 252-261.	1.5	54
41	Effects of parental alcohol rules on risky drinking and related problems in adolescence: Systematic review and meta-analysis. <i>Drug and Alcohol Dependence</i> , 2017, 178, 243-256.	1.6	54
42	Emerging psychoactive substance use among regular ecstasy users in Australia. <i>Drug and Alcohol Dependence</i> , 2012, 124, 19-25.	1.6	52
43	Cannabinoid interventions for PTSD: Where to next?. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2019, 93, 124-140.	2.5	52
44	The recovery of online drug markets following law enforcement and other disruptions. <i>Drug and Alcohol Dependence</i> , 2017, 173, 159-162.	1.6	50
45	The effects of "ecstasy" (MDMA) on visuospatial memory performance: findings from a systematic review with meta-analyses. <i>Human Psychopharmacology</i> , 2012, 27, 113-138.	0.7	49
46	The relationship between age and risky injecting behaviours among a sample of Australian people who inject drugs. <i>Drug and Alcohol Dependence</i> , 2013, 132, 541-546.	1.6	49
47	Refining the excretion factors of methadone and codeine for wastewater analysis " Combining data from pharmacokinetic and wastewater studies. <i>Environment International</i> , 2016, 94, 307-314.	4.8	49
48	Adolescent Alcohol Use Trajectories: Risk Factors and Adult Outcomes. <i>Pediatrics</i> , 2020, 146, .	1.0	49
49	Concordance of ICD-11 and DSM-5 definitions of alcohol and cannabis use disorders: a population survey. <i>Lancet Psychiatry</i> ,the, 2016, 3, 673-684.	3.7	47
50	New psychoactive substance use among regular psychostimulant users in Australia, 2010"2015. <i>Drug and Alcohol Dependence</i> , 2016, 161, 110-118.	1.6	46
51	Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305.	1.7	46
52	Modulation of the endocannabinoid system by sex hormones: Implications for posttraumatic stress disorder. <i>Neuroscience and Biobehavioral Reviews</i> , 2018, 94, 302-320.	2.9	45
53	Risk and benefit perceptions of party drug use. <i>Addictive Behaviors</i> , 2006, 31, 137-142.	1.7	43
54	Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. <i>Pain</i> , 2016, 157, 1489-1498.	2.0	43

#	ARTICLE	IF	CITATIONS
55	Multiply disadvantaged: Health and service utilisation factors faced by homeless injecting drug consumers in Australia. <i>Drug and Alcohol Review</i> , 2015, 34, 379-387.	1.1	42
56	Changes in non-opioid substitution treatment episodes for pharmaceutical opioids and heroin from 2002 to 2011. <i>Drug and Alcohol Dependence</i> , 2015, 149, 212-219.	1.6	40
57	Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. <i>Drug and Alcohol Dependence</i> , 2016, 162, 79-87.	1.6	40
58	Characterising dark net marketplace purchasers in a sample of regular psychostimulant users. <i>International Journal of Drug Policy</i> , 2016, 35, 32-37.	1.6	40
59	Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 17.	1.0	39
60	Prevalence and Correlates of Suicidal Thoughts and Suicide Attempts in People Prescribed Pharmaceutical Opioids for Chronic Pain. <i>Clinical Journal of Pain</i> , 2016, 32, 292-301.	0.8	39
61	Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591.	0.9	39
62	Alcohol Use and Risk Taking Among Regular Ecstasy Users. <i>Substance Use and Misuse</i> , 2006, 41, 1095-1109.	0.7	38
63	A survey of regular ecstasy users' knowledge and practices around determining pill content and purity: Implications for policy and practice. <i>International Journal of Drug Policy</i> , 2006, 17, 464-472.	1.6	37
64	An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 469-494.	0.8	37
65	Motivations for new psychoactive substance use among regular psychostimulant users in Australia. <i>International Journal of Drug Policy</i> , 2017, 43, 23-32.	1.6	36
66	Concordance between the diagnostic guidelines for alcohol and cannabis use disorders in the draft ICD-11 and other classification systems: analysis of data from the WHO's World Mental Health Surveys. <i>Addiction</i> , 2019, 114, 534-552.	1.7	36
67	Dopamine, endocannabinoids and their interaction in fear extinction and negative affect in PTSD. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2021, 105, 110118.	2.5	36
68	Exercise increases plasma THC concentrations in regular cannabis users. <i>Drug and Alcohol Dependence</i> , 2013, 133, 763-767.	1.6	34
69	Monitoring temporal changes in use of two cathinones in a large urban catchment in Queensland, Australia. <i>Science of the Total Environment</i> , 2016, 545-546, 250-255.	3.9	34
70	Parental supply of alcohol and alcohol consumption in adolescence: prospective cohort study. <i>Psychological Medicine</i> , 2017, 47, 267-278.	2.7	34
71	Alcohol use among young Australian adults in May-June 2020 during the COVID-19 pandemic: a prospective cohort study. <i>Addiction</i> , 2021, 116, 3398-3407.	1.7	34
72	The self-reported personal wellbeing of a sample of Australian injecting drug users. <i>Addiction</i> , 2010, 105, 2141-2148.	1.7	33

#	ARTICLE	IF	CITATIONS
73	Effect on the Emotions of Healthy Individuals of Slow Repetitive Transcranial Magnetic Stimulation Applied to the Prefrontal Cortex. <i>Journal of ECT</i> , 2001, 17, 184-189.	0.3	32
74	Factors associated with driving under the influence of alcohol and drugs among an Australian sample of regular ecstasy users. <i>Drug and Alcohol Dependence</i> , 2009, 100, 24-31.	1.6	32
75	Cohort Profile: The Australian Parental Supply of Alcohol Longitudinal Study (APSALS). <i>International Journal of Epidemiology</i> , 2017, 46, e6-e6.	0.9	32
76	Knowledge of Opioid Overdose and Attitudes to Supply of Take-Home Naloxone Among People with Chronic Noncancer Pain Prescribed Opioids. <i>Pain Medicine</i> , 2018, 19, 533-540.	0.9	32
77	Changes in illicit drug use and markets with the COVID-19 pandemic and associated restrictions: findings from the Ecstasy and Related Drugs Reporting System, 2016-20. <i>Addiction</i> , 2022, 117, 182-194.	1.7	31
78	The effects of restricting publicly subsidised temazepam capsules on benzodiazepine use among injecting drug users in Australia. <i>Medical Journal of Australia</i> , 2004, 181, 300-304.	0.8	30
79	An Investigation of Factors Associated with Depressive Symptoms among a Sample of Regular Ecstasy Consumers. <i>Neuropsychobiology</i> , 2010, 61, 215-222.	0.9	30
80	Factors associated with the development of depression in chronic non-cancer pain patients following the onset of opioid treatment for pain. <i>Journal of Affective Disorders</i> , 2015, 184, 72-80.	2.0	30
81	Is khat use disorder a valid diagnostic entity?. <i>Addiction</i> , 2016, 111, 1666-1676.	1.7	30
82	Parents Who Supply Sips of Alcohol in Early Adolescence: A Prospective Study of Risk Factors. <i>Pediatrics</i> , 2016, 137, e20152611.	1.0	30
83	Day-by-day variation in affect, arousal and alcohol consumption in young adults. <i>Drug and Alcohol Review</i> , 2015, 34, 588-594.	1.1	29
84	The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67.	1.6	29
85	Changes in mental health and help-seeking among young Australian adults during the COVID-19 pandemic: a prospective cohort study. <i>Psychological Medicine</i> , 2023, 53, 687-695.	2.7	29
86	Eye movement and visual motion perception in schizophrenia II: global coherent motion as a function of target velocity and stimulus density. <i>Experimental Brain Research</i> , 2007, 182, 415-426.	0.7	28
87	Pharmaceutical opioid analgesic and heroin dependence: How do treatment-seeking clients differ in Australia?. <i>Drug and Alcohol Review</i> , 2011, 30, 291-299.	1.1	28
88	The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018, 5, 155-166.	3.7	28
89	Cognitive, physical, and mental health outcomes between long-term cannabis and tobacco users. <i>Addictive Behaviors</i> , 2018, 79, 178-188.	1.7	28
90	Simultaneous quantification of endocannabinoids, oleoylethanolamide and steroid hormones in human plasma and saliva. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2020, 1152, 122252.	1.2	28

#	ARTICLE	IF	CITATIONS
91	Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016, 159, 42-52.	1.6	27
92	Challenges and opportunities in using wastewater analysis to measure drug use in a small prison facility. <i>Drug and Alcohol Review</i> , 2016, 35, 138-147.	1.1	27
93	The prevalence of pain and analgesia use in the Australian population: Findings from the 2011 to 2012 Australian National Health Survey. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 1403-1410.	0.9	26
94	Contextualising psychological distress among regular ecstasy users: The importance of sociodemographic factors and patterns of drug use. <i>Drug and Alcohol Review</i> , 2010, 29, 243-249.	1.1	24
95	Drug detection dogs in Australia: More bark than bite?. <i>Drug and Alcohol Review</i> , 2012, 31, 778-783.	1.1	24
96	The sources of pharmaceuticals for problematic users of benzodiazepines and prescription opioids. <i>Medical Journal of Australia</i> , 2013, 199, 696-699.	0.8	24
97	Associations of borderline personality with pain, problems with medications and suicidality in a community sample of chronic non-cancer pain patients prescribed opioids for pain. <i>General Hospital Psychiatry</i> , 2015, 37, 434-440.	1.2	24
98	Recent trends in benzodiazepine use by injecting drug users in Victoria and Tasmania. <i>Drug and Alcohol Review</i> , 2002, 21, 363-367.	1.1	23
99	Attitudes in Australia on the upscheduling of over-the-counter codeine to a prescription-only medication. <i>Drug and Alcohol Review</i> , 2018, 37, 257-261.	1.1	23
100	The Epidemiology of Ecstasy Use and Harms in Australia. <i>Neuropsychobiology</i> , 2009, 60, 176-187.	0.9	22
101	I like the old stuff better than the new stuff? Subjective experiences of new psychoactive substances. <i>International Journal of Drug Policy</i> , 2017, 40, 44-49.	1.6	22
102	Drug use and risk among regular injecting drug users in Australia: does age make a difference?. <i>Drug and Alcohol Review</i> , 2008, 27, 357-360.	1.1	21
103	Effect of filtration on morphine and particle content of injections prepared from slow-release oral morphine tablets. <i>Harm Reduction Journal</i> , 2009, 6, 37.	1.3	21
104	Monitoring drug markets in the Internet age and the evolution of drug monitoring systems in Australia. <i>Drug Testing and Analysis</i> , 2014, 6, 840-845.	1.6	21
105	Cannabinoid polymorphisms interact with plasma endocannabinoid levels to predict fear extinction learning. <i>Depression and Anxiety</i> , 2021, 38, 1087-1099.	2.0	21
106	Prevalence of injecting drug use and associated risk behavior among regular ecstasy users in Australia. <i>Drug and Alcohol Dependence</i> , 2006, 83, 210-217.	1.6	20
107	Investigating the Role of Serotonin in Visual Orientation Processing Using an "Ecstasy" (MDMA)-Based Research Model. <i>Neuropsychobiology</i> , 2009, 60, 204-212.	0.9	20
108	Monitoring the Internet for emerging psychoactive substances available to Australia. <i>Drug and Alcohol Review</i> , 2013, 32, n/a-n/a.	1.1	20

#	ARTICLE	IF	CITATIONS
109	The effect of the ecstasy "come-down"™ on the diagnosis of ecstasy dependence. <i>Drug and Alcohol Dependence</i> , 2014, 139, 26-32.	1.6	20
110	The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 51-61.	1.5	20
111	Association between purity of drug seizures and illicit drug loads measured in wastewater in a South East Queensland catchment over a six year period. <i>Science of the Total Environment</i> , 2018, 635, 779-783.	3.9	20
112	Benzodiazepines - Their role in aggression and why GPs should prescribe with caution. <i>Australian Family Physician</i> , 2011, 40, 862-5.	0.5	20
113	Monitoring substance use in prisons: Assessing the potential value of wastewater analysis. <i>Science and Justice - Journal of the Forensic Science Society</i> , 2014, 54, 338-345.	1.3	19
114	Self-Reported Risk-Taking Behavior During Matched-Frequency Sessions of Alcohol Versus Combined Alcohol and Energy Drinks Consumption: Does Co-Ingestion Increase Risk-Taking?. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 911-918.	1.4	19
115	Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medication Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015, 110, 226-237.	1.7	19
116	Associations between alcohol consumption and cardio-metabolic risk factors in young adults. <i>European Journal of Preventive Cardiology</i> , 2017, 24, 1967-1978.	0.8	19
117	Behavioral measures of state impulsivity and their psychometric properties: A systematic review. <i>Personality and Individual Differences</i> , 2018, 135, 67-79.	1.6	19
118	Cannabis use in patients 3 months after ceasing nabiximols for the treatment of cannabis dependence: Results from a placebo-controlled randomised trial. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108220.	1.6	19
119	Driving under the influence among frequent ecstasy consumers in Australia: Trends over time and the role of risk perceptions. <i>Drug and Alcohol Dependence</i> , 2014, 144, 218-224.	1.6	18
120	Early Adolescent Alcohol Use: Are Sipping and Drinking Distinct?. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1805-1813.	1.4	18
121	Cognitive Impairment Following Consumption of Alcohol With and Without Energy Drinks. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 733-742.	1.4	18
122	Evaluation of Monitoring Schemes for Wastewater-Based Epidemiology to Identify Drug Use Trends Using Cocaine, Methamphetamine, MDMA and Methadone. <i>Environmental Science & Technology</i> , 2016, 50, 4760-4768.	4.6	18
123	Tobacco and e-cigarette use amongst illicit drug users in Australia. <i>Drug and Alcohol Dependence</i> , 2016, 159, 35-41.	1.6	18
124	Trends in reports of driving following illicit drug consumption among regular drug users in Australia, 2007-2013: Has random roadside drug testing had a deterrent effect?. <i>Accident Analysis and Prevention</i> , 2017, 104, 146-155.	3.0	17
125	The metabolomic signatures of alcohol consumption in young adults. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 840-849.	0.8	17
126	Trends in methamphetamine use, markets and harms in Australia, 2003-2019. <i>Drug and Alcohol Review</i> , 2022, 41, 1041-1052.	1.1	17

#	ARTICLE	IF	CITATIONS
127	Sipping, Drinking, and Early Adolescent Alcohol Consumption: A Cautionary Note. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 350-354.	1.4	16
128	Guilt-proneness is associated with the use of protective behavioral strategies during episodes of alcohol use. <i>Addictive Behaviors</i> , 2018, 79, 120-123.	1.7	16
129	Adherence to the Caffeine Intake Guideline during Pregnancy and Birth Outcomes: A Prospective Cohort Study. <i>Nutrients</i> , 2018, 10, 319.	1.7	16
130	Parental supply of sips and whole drinks of alcohol to adolescents and associations with binge drinking and alcohol-related harms: A prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2020, 215, 108204.	1.6	16
131	Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592.	3.2	16
132	Transition to and from injecting drug use among regular ecstasy users. <i>Addictive Behaviors</i> , 2010, 35, 909-912.	1.7	15
133	Typology of Alcohol Mixed with Energy Drink Consumers: Motivations for Use. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 1083-1092.	1.4	15
134	Chronic cannabis use and ERP correlates of visual selective attention during the performance of a flanker go/nogo task. <i>Biological Psychology</i> , 2015, 110, 115-125.	1.1	15
135	Energy drink use frequency among an international sample of people who use drugs: Associations with other substance use and well-being. <i>Drug and Alcohol Dependence</i> , 2017, 174, 70-79.	1.6	15
136	Recreational 3,4-methylenedioxymethamphetamine or "ecstasy": Current perspective and future research prospects. <i>Journal of Psychopharmacology</i> , 2017, 31, 959-966.	2.0	15
137	Assessing the validity of the Australian Treatment Outcomes Profile for telephone administration in drug health treatment populations. <i>Drug and Alcohol Review</i> , 2020, 39, 441-446.	1.1	15
138	Endocannabinoid reactivity to acute stress: Investigation of the relationship between salivary and plasma levels. <i>Biological Psychology</i> , 2021, 159, 108022.	1.1	15
139	Trends in cocaine use, markets and harms in Australia, 2003–2019. <i>Drug and Alcohol Review</i> , 2021, 40, 946-956.	1.1	15
140	Chloroform-based liquid-liquid extraction and LC–MS/MS quantification of endocannabinoids, cortisol and progesterone in human hair. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2021, 201, 114103.	1.4	15
141	Daily and Spaced Treatment with Transcranial Magnetic Stimulation in Major Depression: A Pilot Study. <i>Australian and New Zealand Journal of Psychiatry</i> , 2006, 40, 759-763.	1.3	14
142	Commentary on <i>Ort et al.</i> (2014): What next to deliver on the promise of large scale sewage-based drug epidemiology?. <i>Addiction</i> , 2014, 109, 1353-1354.	1.7	14
143	Awareness of energy drink intake guidelines and associated consumption practices: a cross-sectional study. <i>BMC Public Health</i> , 2015, 16, 6.	1.2	14
144	Young adults who mix alcohol with energy drinks: Typology of risk-taking behaviour. <i>Addictive Behaviors</i> , 2015, 45, 252-258.	1.7	14

#	ARTICLE	IF	CITATIONS
145	Typology of alcohol consumers in five Australian nighttime entertainment districts. <i>Drug and Alcohol Review</i> , 2016, 35, 539-548.	1.1	14
146	Perception of intoxication in a field study of the night-time economy: Blood alcohol concentration, patron characteristics, and event-level predictors. <i>Addictive Behaviors</i> , 2018, 76, 195-200.	1.7	14
147	Parental supply of alcohol as a predictor of adolescent alcohol consumption patterns: A prospective cohort. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107529.	1.6	14
148	Eye movement and visual motion perception in schizophrenia I: Apparent motion evoked smooth pursuit eye movement reveals a hidden dysfunction in smooth pursuit eye movement in schizophrenia. <i>Experimental Brain Research</i> , 2007, 182, 399-413.	0.7	13
149	Self-reported physiological and psychological side-effects of an acute alcohol and energy drink dose. <i>Appetite</i> , 2014, 76, 60-65.	1.8	13
150	Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. <i>International Journal of Drug Policy</i> , 2015, 26, 1265-1272.	1.6	13
151	Routine opioid outcome monitoring in community pharmacy: Pilot implementation study protocol. <i>Research in Social and Administrative Pharmacy</i> , 2019, 15, 1047-1055.	1.5	13
152	Profile and correlates of injecting-related injuries and diseases among people who inject drugs in Australia. <i>Drug and Alcohol Dependence</i> , 2020, 216, 108267.	1.6	13
153	Evaluation of Peakmaster for computer-aided multivariate optimisation of a CE separation of 17 antipsychotic drugs using minimal experimental data. <i>Electrophoresis</i> , 2009, 30, 839-847.	1.3	12
154	The impact of comorbid cannabis and methamphetamine use on mental health among regular ecstasy users. <i>Addictive Behaviors</i> , 2012, 37, 1058-1062.	1.7	12
155	Estimating the proportion of prescription opioids that is consumed by people who inject drugs in Australia. <i>Drug and Alcohol Review</i> , 2013, 32, n/a-n/a.	1.1	12
156	A cross-sectional analysis of over-the-counter codeine use among an Australian sample of people who regularly inject drugs. <i>Drug and Alcohol Review</i> , 2013, 32, 574-581.	1.1	12
157	Detecting impairment: Sensitive cognitive measures of dose-related acute alcohol intoxication. <i>Journal of Psychopharmacology</i> , 2015, 29, 436-446.	2.0	12
158	The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 90-94.	1.5	12
159	Age-related differences in patterns of criminal activity among a large sample of polydrug injectors in Australia. <i>Journal of Substance Use</i> , 2016, 21, 48-56.	0.3	12
160	Antidepressant Use Among People Prescribed Opioids for Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 2450-2458.	0.9	12
161	Combining transdermal and breath alcohol assessments, real-time drink logs and retrospective self-reports to measure alcohol consumption and intoxication across a multi-day music festival. <i>Drug and Alcohol Review</i> , 2021, 40, 1112-1121.	1.1	12
162	High-Motivation for Alcohol: What are the Practical Effects of Energy Drinks on Alcohol Priming?. <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 185-187.	1.4	11

#	ARTICLE	IF	CITATIONS
163	Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. <i>Drug and Alcohol Review</i> , 2014, 33, 27-32.	1.1	11
164	Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133.	1.6	11
165	Trends in PIEDs use among male clients of needle "syringe programs in Queensland, Australia; 2007-2015. <i>International Journal of Drug Policy</i> , 2017, 46, 74-78.	1.6	11
166	Typology of new psychoactive substance use among the general Australian population. <i>Drug and Alcohol Dependence</i> , 2018, 188, 126-134.	1.6	11
167	LiMA: a study protocol for a randomised, double-blind, placebo controlled trial of lisdexamfetamine for the treatment of methamphetamine dependence. <i>BMJ Open</i> , 2018, 8, e020723.	0.8	11
168	Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. <i>Addiction</i> , 2019, 114, 389-399.	1.7	11
169	Safety and tolerability of oral lisdexamfetamine in adults with methamphetamine dependence: a phase-2 dose-escalation study. <i>BMJ Open</i> , 2021, 11, e044696.	0.8	11
170	Effectiveness of and challenges faced by surveillance systems. <i>Drug Testing and Analysis</i> , 2011, 3, 635-641.	1.6	10
171	Implementing real-time prescription drug monitoring: Are we ready?. <i>Drug and Alcohol Review</i> , 2014, 33, 463-465.	1.1	10
172	Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622.	1.1	10
173	Geographic Variation in Health Service Use and Perceived Access Barriers for Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy. <i>Pain Medicine</i> , 2016, 17, 2003-2016.	0.9	10
174	Sleep Quality Among People Living With Chronic Noncancer Pain. <i>Clinical Journal of Pain</i> , 2016, 32, 380-387.	0.8	10
175	Nature versus intensity of intoxication: Co-ingestion of alcohol and energy drinks and the effect on objective and subjective intoxication. <i>Drug and Alcohol Dependence</i> , 2017, 180, 292-303.	1.6	10
176	The overall effect of parental supply of alcohol across adolescence on alcohol-related harms in early adulthood—a prospective cohort study. <i>Addiction</i> , 2020, 115, 1833-1843.	1.7	10
177	Routine opioid outcome monitoring in community pharmacy: Outcomes from an open-label single-arm implementation-effectiveness pilot study. <i>Research in Social and Administrative Pharmacy</i> , 2020, 16, 1694-1701.	1.5	10
178	Alprazolam Prescribing in Tasmania: A Two-Fold Intervention Designed to Reduce Inappropriate Prescribing and Concomitant Opiate Prescription. <i>Australasian Psychiatry</i> , 2009, 17, 300-305.	0.4	9
179	Detouring Civil Liberties?. <i>Griffith Law Review</i> , 2010, 19, 330-349.	0.6	9
180	Sexual and injecting risk behaviours among regular ecstasy users. <i>Addictive Behaviors</i> , 2010, 35, 157-160.	1.7	9

#	ARTICLE	IF	CITATIONS
181	Pharmaceutical drugs: The delicate balance between reducing pain and reducing harm. <i>Drug and Alcohol Review</i> , 2011, 30, 233-235.	1.1	9
182	Effects of Filtration on the Presence of Particulate and Oxycodone Content of Injections Prepared from Crushed OxyContin® Tablets. <i>Current Drug Safety</i> , 2012, 7, 218-224.	0.3	9
183	Residual effects of ecstasy (3,4-methylenedioxyamphetamine) on low level visual processes. <i>Human Psychopharmacology</i> , 2012, 27, 226-234.	0.7	9
184	Filtration of crushed tablet suspensions has potential to reduce infection incidence in people who inject drugs. <i>Drug and Alcohol Review</i> , 2015, 34, 67-73.	1.1	9
185	Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769.	0.9	9
186	Measuring Alcohol Use-Related Shame and Guilt: Development and Validation of the Perceptions of Drinking Scale. <i>Substance Use and Misuse</i> , 2020, 55, 441-451.	0.7	9
187	Assessing the concurrent validity, inter-rater reliability and test-retest reliability of the Australian Treatment Outcomes Profile (ATOP) in alcohol and opioid treatment populations. <i>Addiction</i> , 2021, 116, 1245-1255.	1.7	9
188	Clinical correlates and outcomes associated with pregabalin use among people prescribed opioids for chronic non-cancer pain: A five-year prospective cohort study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 3092-3104.	1.1	9
189	Correlates of pain in an in-treatment sample of opioid-dependent people. <i>Drug and Alcohol Review</i> , 2013, 32, 489-494.	1.1	8
190	Study protocol: a dose-escalating, phase-2 study of oral lisdexamfetamine in adults with methamphetamine dependence. <i>BMC Psychiatry</i> , 2016, 16, 428.	1.1	8
191	Health service utilisation by people living with chronic non-cancer pain: findings from the Pain and Opioids IN Treatment (POINT) study. <i>Australian Health Review</i> , 2016, 40, 490.	0.5	8
192	Co-ingestion of energy drinks with alcohol and other substances among a sample of people who regularly use ecstasy. <i>Drug and Alcohol Review</i> , 2016, 35, 352-358.	1.1	8
193	Combined use of alcohol and energy drinks: Dose relationship with self-reported physiological stimulation and sedation side effects. <i>Addictive Behaviors</i> , 2017, 71, 68-74.	1.7	8
194	New psychoactive substances: Purchasing and supply patterns in Australia. <i>Human Psychopharmacology</i> , 2017, 32, e2577.	0.7	8
195	Verbal Learning and Memory in Cannabis and Alcohol Users: An Event-Related Potential Investigation. <i>Frontiers in Psychology</i> , 2017, 8, 2129.	1.1	8
196	Targeting at-risk samples through brief face-to-face interviews in night-time entertainment precincts. <i>Journal of Substance Use</i> , 2018, 23, 353-357.	0.3	8
197	Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88.	0.9	8
198	Parent hazardous drinking and their children's alcohol use in early and mid-adolescence: prospective cohort study. <i>European Journal of Public Health</i> , 2019, 29, 736-740.	0.1	8

#	ARTICLE	IF	CITATIONS
199	Trajectories of alcohol-induced blackouts in adolescence: early risk factors and alcohol use disorder outcomes in early adulthood. <i>Addiction</i> , 2021, 116, 2039-2048.	1.7	8
200	Moody booze: Introducing the special section on affect regulation and substance use. <i>Drug and Alcohol Review</i> , 2015, 34, 569-570.	1.1	7
201	The use of paracetamol (acetaminophen) among a community sample of people with chronic non-cancer pain prescribed opioids. <i>International Journal of Clinical Practice</i> , 2015, 69, 1366-1376.	0.8	7
202	Injection of Pharmaceuticals Designed for Oral Use: Harms Experienced and Effective Harm Reduction Through Filtration. <i>Current Topics in Behavioral Neurosciences</i> , 2016, 34, 77-98.	0.8	7
203	Treating codeine dependence with buprenorphine: Dose requirements and induction outcomes from a retrospective case series in New South Wales, Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 70-75.	1.1	7
204	A nationwide study of the extent and factors associated with fentanyl use in Australia. <i>Research in Social and Administrative Pharmacy</i> , 2018, 14, 303-308.	1.5	7
205	Stopping khat use: Predictors of success in an unaided quit attempt. <i>Drug and Alcohol Review</i> , 2018, 37, S235-S239.	1.1	7
206	Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , 2020, 39, 128-134.	1.1	7
207	Validation of the Australian Treatment Outcomes Profile for use in clients with cannabis dependence. <i>Drug and Alcohol Review</i> , 2020, 39, 356-364.	1.1	7
208	What predicts pharmacists' engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy. <i>International Journal of Clinical Pharmacy</i> , 2021, 43, 420-429.	1.0	7
209	Khat withdrawal symptoms among chronic khat users following a quit attempt: An ecological momentary assessment study.. <i>Psychology of Addictive Behaviors</i> , 2018, 32, 320-326.	1.4	7
210	A review of caffeine use as a risk or protective factor for women's health and pregnancy. <i>Current Opinion in Psychiatry</i> , 2017, 30, 253-259.	3.1	7
211	The expectancy valence model of the Iowa Gambling Task: Can it produce reliable estimates for individuals?. <i>Journal of Mathematical Psychology</i> , 2015, 64-65, 17-34.	1.0	6
212	How does the use of multiple needles/syringes per injecting episode impact on the measurement of individual level needle and syringe program coverage?. <i>International Journal of Drug Policy</i> , 2017, 46, 99-106.	1.6	6
213	A systematic review of event-level measures of risk-taking behaviors and harms during alcohol intoxication. <i>Addictive Behaviors</i> , 2019, 99, 106101.	1.7	6
214	Prevalence and associations of quetiapine fumarate misuse among an Australian national city sample of people who regularly inject drugs. <i>Addiction</i> , 2014, 109, 295-302.	1.7	5
215	Randomised controlled trial (RCT) of daily aerobic exercise for inpatient cannabis withdrawal: A study protocol. <i>Mental Health and Physical Activity</i> , 2017, 13, 57-67.	0.9	5
216	Using the Severity of Dependence Scale to screen for DSM-5 khat use disorder. <i>Human Psychopharmacology</i> , 2018, 33, e2653.	0.7	5

#	ARTICLE	IF	CITATIONS
217	Understanding an emerging treatment population: Protocol for and baseline characteristics of a prospective cohort of people receiving treatment for pharmaceutical opioid dependence. <i>Drug and Alcohol Review</i> , 2018, 37, 887-896.	1.1	5
218	Alprazolam use among a sample of Australians who inject drugs: Trends up to six years post regulatory changes. <i>International Journal of Drug Policy</i> , 2020, 79, 102721.	1.6	5
219	Profile and correlates of colorimetric reagent kit use among people who use ecstasy/MDMA and other illegal stimulants in Australia. <i>International Journal of Drug Policy</i> , 2021, 97, 103334.	1.6	5
220	Trajectories of parental and peer supply of alcohol in adolescence and associations with later alcohol consumption and harms: A prospective cohort study. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109533.	1.6	5
221	Postexercise facilitation appears durable in normal subjects. <i>Psychiatry and Clinical Neurosciences</i> , 2001, 55, 157-159.	1.0	4
222	Valid Points, But the Trends Remain: A Response to Rossheim, Suzuki, and Thombs (In Press). <i>Alcoholism: Clinical and Experimental Research</i> , 2013, 37, 2171-2174.	1.4	4
223	A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1321-1333.	0.9	4
224	Inhibiting automatic negative social responses in alcohol intoxication: interactions with theory of mind ability and level of task guidance. <i>Psychopharmacology</i> , 2018, 235, 1221-1232.	1.5	4
225	Alcohol Text Messages: A Developmental Study. <i>International Journal of Mental Health and Addiction</i> , 2018, 16, 1125-1139.	4.4	4
226	Aggression in the Australian night time economy: A comparison of alcohol only versus alcohol and illicit drug consumption. <i>Drug and Alcohol Review</i> , 2019, 38, 744-749.	1.1	4
227	The association between parental supply of alcohol and supply from other sources to young people: a prospective cohort. <i>Addiction</i> , 2020, 115, 2140-2147.	1.7	4
228	Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021, 4, e213059.	2.8	4
229	Gender differences in the supply of alcohol to adolescent daughters and sons. <i>American Journal of Drug and Alcohol Abuse</i> , 2021, 47, 508-520.	1.1	4
230	Commentary on Fidler <i>et al.</i> (2011): Identifying quitters who are at increased risk of relapse "where to from here?". <i>Addiction</i> , 2011, 106, 639-640.	1.7	3
231	Opioid agonist doses for oxycodone and morphine dependence: Findings from a retrospective case series. <i>Drug and Alcohol Review</i> , 2017, 36, 311-316.	1.1	3
232	Parent characteristics associated with approval of their children drinking alcohol from ages 13 to 16 years: prospective cohort study. <i>Australian and New Zealand Journal of Public Health</i> , 2018, 42, 347-353.	0.8	3
233	Commentary on "Sex differences in the effect of cannabinoid type 1 receptor deletion on locus coeruleus-norepinephrine neurons and corticotropin releasing factor-mediated responses". <i>European Journal of Neuroscience</i> , 2019, 49, 1210-1211.	1.2	3
234	Mixing alcohol and energy drinks: associations with risk-taking, alcohol consumption and motivations in a New Zealand sample. <i>Journal of Substance Use</i> , 2020, 25, 157-162.	0.3	3

#	ARTICLE	IF	CITATIONS
235	Use of alcohol swabs to clean injecting sites among people who regularly inject drugs in Australia. <i>Drug and Alcohol Review</i> , 2020, 39, 83-92.	1.1	3
236	Validation of the OWLS, a Screening Tool for Measuring Prescription Opioid Use Disorder in Primary Care. <i>Pain Medicine</i> , 2020, 21, 2757-2764.	0.9	3
237	Validity and Reliability of the Computer-Administered Routine Opioid Outcome Monitoring (ROOM) Tool. <i>Pain Medicine</i> , 2020, 21, 3645-3654.	0.9	3
238	Patterns and correlates of prescribed and non-prescribed pregabalin use among a sample of people who inject drugs in Australia. <i>Drug and Alcohol Review</i> , 2020, 39, 568-574.	1.1	3
239	Trends and characteristics of extra-medical use of quetiapine among people who regularly inject drugs in Australia, 2011–2018. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108636.	1.6	3
240	A prospective cohort study evaluating the impact of upscheduling codeine in Australia among frequent users of codeine. <i>Addiction</i> , 2022, 117, 677-686.	1.7	3
241	Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494.	1.7	3
242	Choosing a Cut-Off on the Severity of Dependence Scale for Ecstasy Use. <i>The Open Addiction Journal</i> , 2011, 4, 13-14.	0.5	3
243	Is Mindfulness a Noticeable Quality? Development and Validation of the Observed Mindfulness Measure. <i>Journal of Psychopathology and Behavioral Assessment</i> , 2022, 44, 165-185.	0.7	3
244	Substance Use and Sex Index (SUSI): First stage development of an assessment tool to measure behaviour change in sexualised drug use for substance use treatment studies. <i>International Journal of Drug Policy</i> , 2018, 55, 165-168.	1.6	2
245	“Ice Rushes”™, Data Shadows and Methylamphetamine Use in Rural Towns: Wastewater Analysis. <i>Current Issues in Criminal Justice</i> , 2018, 29, 195-208.	0.8	2
246	A Systematic Review and Meta-Analysis of Cognitive Performance among People with Chronic Use of Opioids for Chronic Non-Cancer Pain. <i>Pain Medicine</i> , 2021, 22, 979-993.	0.9	2
247	Self-reported recent testing and diagnosis for sexually transmitted infections among regular ecstasy users in Australia, 2011-2012. <i>Drug and Alcohol Review</i> , 2014, 33, 211-214.	1.1	1
248	New applications of wastewater analyses for assessing substance use. <i>Drug and Alcohol Review</i> , 2016, 35, 125-127.	1.1	1
249	Energy drinks, alcohol and cardiovascular functioning. <i>Drug and Alcohol Dependence</i> , 2018, 185, 423-424.	1.6	1
250	What do we know about alcohol mixed with energy drink (AmED) use in Australia? Expanding local evidence. <i>Public Health Research and Practice</i> , 2018, 28, .	0.7	1
251	Impact of Removing Nonprescription Codeine in Australia: Protocol for a Prospective Cohort Study. <i>JMIR Research Protocols</i> , 2020, 9, e15540.	0.5	1
252	A Typology of Predictive Risk Factors for Non-Adherent Medication-Related Behaviors among Chronic Non-Cancer Pain Patients Prescribed Opioids: A Cohort Study. <i>Pain Physician</i> , 2016, 19, E421-34.	0.3	1

#	ARTICLE	IF	CITATIONS
253	Mood, sleep and pain comorbidity outcomes in cannabis dependent patients: Findings from a nabiximols versus placebo randomised controlled trial. <i>Drug and Alcohol Dependence</i> , 2022, 234, 109388.	1.6	1
254	Assessing drivingâ€relevant attentional impairment after a multiday drinking session: A twoâ€phase pilot study. <i>Alcoholism: Clinical and Experimental Research</i> , 2022, 46, 628-640.	1.4	1
255	Definition matters: assessment of tolerance to the effects of alcohol in a prospective cohort study of emerging adults. <i>Addiction</i> , 2022, 117, 2955-2964.	1.7	1
256	Prime Time for In Situ Measurement: What Are the Drivers and Implications of Energy Drink Coâ€Ingestion on Alcohol Priming?. <i>Alcoholism: Clinical and Experimental Research</i> , 2016, 40, 2073-2075.	1.4	0
257	Trends in methamphetamine and opioid use among clients of needleâ€syringe programs in Queensland, Australia: 2007â€2015. <i>Drug and Alcohol Review</i> , 2019, 38, 159-168.	1.1	0
258	Clinical Significance and Outcomes in Trial of Nabiximols for Treatment of Cannabis Dependenceâ€Reply. <i>JAMA Internal Medicine</i> , 2020, 180, 163.	2.6	0
259	962 Adolescent Alcohol Use Trajectories: A Prospective Study of Risk Factors and Adulthood AUD Outcomes. <i>International Journal of Epidemiology</i> , 2021, 50, .	0.9	0
260	Are shame and guilt personality styles associated with different alcohol use-related outcome expectancies?. <i>Journal of Substance Use</i> , 0, , 1-4.	0.3	0
261	MDMA: Neurohormonal, Neurocognitive, and Psychobiological Aspects of Recreational Ecstasy. <i>The Open Addiction Journal</i> , 2009, 2, 24-27.	0.5	0
262	The experience of physiological and psychosocial alcoholâ€related harms across adolescence and its association with alcohol use disorder in early adulthood: A prospective cohort study. <i>Alcoholism: Clinical and Experimental Research</i> , 2021, 45, 2518-2527.	1.4	0